Effects of carboxymethyl-modified hemicellulose on activity of T lymphocytes and amount of immunocytes
Abstract
Carboxymethyl-modified hemicellulose (CMMHC) is a new antitumor drug produced by Department of Wood Chemistry of Nanjing Forestry College. In this paper, the effects of CMMHC on human T cells in vitro were studied by two experiments： Ea rosette formation and lymphocyte transformation. The results showed： (1) CMMHC l0μg/ml raised the Ea rosette forming cell% (EaRFC%) of lymphocytes by 21.7±9.1% (P<0.01)， and accelerated the restoration of the EaRFC% of trypsin-treated lymphocytes； (2) CMMHC 1μg/ml enhanced the response of lymphocytes to low-dosage (0.2%， vol/vol) PHAM (cpm increased by 37±17%，P<0.
On d 8 after ip CMMHC, the immunocytes in peripheral blood and peritoneal fluid of mice were collected. CMMHC raised the amount of lymphocytes (by 59-100%) and other leukocytes (by about 60%) in peripheral blood, and the amount of macrophages (by 70-140%) and lymphocytes (by about 70%) in peritoneal fluid, but the amount of peritoneal polymorphonuclear leukocytes showed no change (p>0.05), suggesting that CMMHC did not cause inflammatory reactions.
The results suggest that CMMHC augments cellular immunity by enhancing the number and activity of immunocytes.
Keywords:
On d 8 after ip CMMHC, the immunocytes in peripheral blood and peritoneal fluid of mice were collected. CMMHC raised the amount of lymphocytes (by 59-100%) and other leukocytes (by about 60%) in peripheral blood, and the amount of macrophages (by 70-140%) and lymphocytes (by about 70%) in peritoneal fluid, but the amount of peritoneal polymorphonuclear leukocytes showed no change (p>0.05), suggesting that CMMHC did not cause inflammatory reactions.
The results suggest that CMMHC augments cellular immunity by enhancing the number and activity of immunocytes.